I. Tusquets

J. Mayordomo, I. Tusquets, A. Llombart-Cussac, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Advanced breast cancer: chemotherapy phase III trials that change a standard

I. Tusquets, I. Álvarez, M. A. Seguí, 2007, Anti-cancer drugs.

Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients

B. Lloveras, I. Tusquets, M. Monzó, 2015 .

Bone health evaluation one year after aromatase inhibitors completion.

A. Díez-Pérez, S. Servitja, I. Tusquets, 2018, Bone.

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study

A. Díez-Pérez, J. Albanell, S. Servitja, 2020, Therapeutic advances in medical oncology.

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study

A. Díez-Pérez, S. Servitja, I. Tusquets, 2019, Breast Cancer Research and Treatment.

Vitamin D levels in Mediterranean breast cancer patients, compared to healthy women

S. Servitja, I. Tusquets, M. García-Pérez, 2019 .

Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women.

A. Díez-Pérez, S. Servitja, I. Tusquets, 2018, Maturitas.

215 Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial

J. Carles, I. Tusquets, R. Ibeas, 1997 .

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

A. Lluch, I. Tusquets, I. Álvarez, 2014, Critical reviews in oncology/hematology.

High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor‐positive metastatic breast cancer: A confirmatory prospective study

J. Mayordomo, B. Lloveras, I. Tusquets, 2007, Cancer.

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer

B. Lloveras, I. Tusquets, M. Monzó, 2005, Breast Cancer Research.

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.

S. Serrano, F. Rojo, J. Yélamos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer

F. Rojo, J. Albanell, L. Espinosa, 2013, Oncotarget.

Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer.

I. Tusquets, Á. Arcusa, L. Cirera, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

F. Rojo, J. Yélamos, J. Albanell, 2014, European journal of cancer.

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

A. Gonzalez-Perez, F. Rojo, J. Albanell, 2016, British Journal of Cancer.

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.

A. Díez-Pérez, S. Servitja, I. Tusquets, 2015, Journal of molecular endocrinology.

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

Beatriz Bellosillo, Ignasi Tusquets, Rosario Perona, 2009, Clinical Cancer Research.

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

S. Serrano, F. Solé, M. Salido, 2005, Breast Cancer Research.

Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study.

S. Serrano, J. Cigudosa, F. Solé, 2012, Cancer genetics.

Joan Maragall: Poet, intellectual and thinker

I. Tusquets, 2014 .

Supportive care for patients with early breast cancer

A. Lluch, I. Tusquets, I. Álvarez, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole

J. Mayordomo, I. Tusquets, E. Alba, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Current controversies in the management of early breast cancer

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study

A. Díez-Pérez, J. Albanell, S. Servitja, 2011, Breast Cancer Research and Treatment.

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.

A. Díez-Pérez, J. Albanell, S. Servitja, 2010, Maturitas.

Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.

E. Campo, S. Serrano, J. Albanell, 2006, Endocrine-related cancer.

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial

S. González, I. Tusquets, A. Barnadas, 2009, British Journal of Cancer.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

F. Rojo, J. Albanell, A. Lluch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

E. Campo, S. Serrano, J. Albanell, 2006 .

Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors

E. Zamora, I. Tusquets, J. Vendrell, 2018, European journal of cancer care.

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.

A. Díez-Pérez, J. Albanell, S. Servitja, 2012, Breast.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer

F. Rojo, L. Comerma, J. Albanell, 2019, Cancer Immunology Research.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

F. Rojo, J. Albanell, S. Servitja, 2017, Front. Immunol..

Perinatal and childhood factors and risk of breast cancer subtypes in adulthood.

Juan Pablo Barrio Lera, V. Moreno, M. Kogevinas, 2016, Cancer epidemiology.

Total Effective Xenoestrogen Burden in Serum Samples and Risk for Breast Cancer in a Population-Based Multicase–Control Study in Spain

Marcela Guevara, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, 2016, Environmental health perspectives.

Cancer bioMarkers database

Rodrigo Dienstmann, Jordi Rodon, Michael Philipp Schroeder, 2016 .

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer

S. Servitja, I. Tusquets, L. Calvo, 2011, Anti-cancer drugs.

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial.

E. Zamora, I. Tusquets, M. Margelí, 2019, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

Current controversies in the management of breast cancer

J. Albanell, A. Lluch, P. Gascón, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Activation of nuclear factor- j B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

E. Campo, S. Serrano, J. Albanell, 2006 .

Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study)

I. Tusquets, M. Méndez, E. E. Arranz, 2009, Clinical and Translational Oncology.

The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials.

J. Albanell, A. Lluch, I. Tusquets, 2007, Clinical breast cancer.

Current perspectives of treatment of ductal carcinoma in situ.

A. Lluch, I. Tusquets, M. Margelí, 2010, Cancer treatment reviews.

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

S. Servitja, I. Tusquets, X. Nogués, 2015, Therapeutic advances in medical oncology.

A comparative study of HER2/neu amplification and overexpression using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients

S. Serrano, F. Solé, M. Salido, 2002, Revista de Oncología.

Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.

A. Lluch, I. Tusquets, M. Margelí, 2008, Cancer treatment reviews.

Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates

A. Díez-Pérez, S. Servitja, I. Tusquets, 2020, Journal of Bone and Mineral Research.

Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway

X. Castells, F. Rojo, J. Albanell, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer.

J. Mayordomo, I. Tusquets, M. Muñoz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study

V. Moreno, M. Kogevinas, A. Tardón, 2016, PloS one.

Breast density, benign breast disease, and risk of breast cancer over time

X. Castells, C. Vidal, I. Tusquets, 2021, European Radiology.

Abstract P2-01-06: Association between Circulating Tumor Cells and Bone Turnover Markers in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study)

I. Tusquets, M. Margelí, L. Calvo, 2012 .

Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Richard G. Moore, B. Monk, Aalok Kumar, 2021, Gynecologic Oncology.

An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval

J. Albanell, S. Servitja, M. Martínez-García, 2014, Anti-cancer drugs.

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.

J. Carles, J. Albanell, I. Tusquets, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial.

I. Tusquets, M. Margelí, A. Barnadas, 2004, Journal of Clinical Oncology.

Gene Expression Pro fi ling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway

X. Castells, F. Rojo, J. Albanell, 2014 .

Changes in the treatment of Breast Cancer Madrid , Spain 1 – 3 June 2005

B. Lloveras, I. Tusquets, M. Monzó, 2015 .

Lecture S 5 Present situation and future of genetic profiling for prognosis and treatment

B. Lloveras, I. Tusquets, M. Monzó, 2015 .

Gene expression profile-based predictors of response to chemotherapy

B. Lloveras, I. Tusquets, M. Monzó, 2005, Breast Cancer Research.

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma

B. Lloveras, I. Tusquets, M. Monzó, 2008, Clinical Cancer Research.